International Stem Cell ISCO
OTC ISCO
$0.27 +0.01 (+3.85%)
At close: Oct 15, 2026 · 4:00 PM EDT

International Stem Cell (ISCO) Construction in Progress (2014)

Updated

International Stem Cell (ISCO) posted Construction in Progress of $64,000 for Q3 2014, up 156.0% from the prior quarter.

Analysis

International Stem Cell (ISCO) Construction in Progress (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn -
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn -
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn -
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn -
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn -
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn -
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn -
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn -
10 International Stem Cell 2.08 Mn -1.89 Mn 1.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2014 64,000.00
Jun 30, 2014 25,000.00
API Access

International Stem Cell Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=ISCO&period=max&api_key=YOUR_API_KEY